Home › Companies › KURA ONCOLOGY INC. › 2023-2024

KURA ONCOLOGY INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and KURA ONCOLOGY INC.’s Form 8-K, filed June 7, 2024 (Item 5.07 on EDGAR). Page generated October 18, 2026.

5Ballot items
183Asset managers
1,100Fund votes
June 5, 2024Meeting date

Results at a glance

Meeting of June 5, 2024: 5 items on KURA ONCOLOGY INC.’s Form 8-K, filed June 7, 2024: 3 approved · 2 without a stated outcome.

Material dissent

None.

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore KURA ONCOLOGY INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by KURA ONCOLOGY INC.

These tallies are KURA ONCOLOGY INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 7, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

KURA ONCOLOGY INC. — official shareholder meeting results, meeting held June 5, 2024
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Troy E. Wilson, Ph.D., J.D.	59,332,182	--	--	7,740,382	2,690,089	88%	Not verified	—
Elect Director: Faheem Hasnain	59,745,514	--	--	7,327,050	2,690,089	89%	Not verified	—
2. Ratification of the Selection of Independent Registered Public Accounting Firm	69,596,811	56,740	109,102	--	--	99.9%	Approved	—
3. Advisory Vote on Executive Compensation	61,538,693	5,449,767	111,285	--	2,662,908	92%	Approved	—
4. Approval of our Amended 2014 Plan	53,621,818	11,993,394	1,484,533	--	2,662,908	82%	Approved	—

Source: KURA ONCOLOGY INC., Form 8-K, filed with the SEC on June 7, 2024 — read the filing on EDGAR.

How asset managers voted at the KURA ONCOLOGY INC. 2023-2024 meeting

Each item below shows how the 183 asset managers that disclosed a KURA ONCOLOGY INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Faheem Hasnain

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%

FOR: 59,745,514WITHHELD: 7,327,050

Details: description as filed, official tally, votes by 58 asset managers

Description as filed by funds: Election of two Class I directors for three-year terms: Faheem Hasnain

KURA ONCOLOGY INC.’s own tally for this item (“Elect Director: Faheem Hasnain”): 59,745,514 for, 7,327,050 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 58 asset managers below reported 14,540,147 for, 1,928,217 withheld.

FOR

FOR: 14,540,147WITHHOLD: 1,928,217

Largest asset managers voting on “Election of two Class I directors for three-year terms: Faheem Hasnain” at KURA ONCOLOGY INC., 2023-2024
Asset manager	For	Withheld	Vote
Vanguard	3,968,562	0	For
BlackRock	3,144,096	0	For
State Street	2,554,088	37,562	For
Fidelity	1,706,693	0	For
Dimensional	0	996,915	Withhold
FRANKLIN STRATEGIC SERIES	967,982	0	For
Charles Schwab	599,027	0	For
JPMorgan	305,460	0	For
Direxion Shares ETF Trust	0	213,276	Withhold
Invesco	203,663	0	For
Equitable	107,966	83,100	Mixed
TIAA	175,690	0	For
Russell Investments	150,483	0	For
QUANTITATIVE MASTER SERIES LLC	131,528	0	For
Lincoln Financial	82,663	38,615	Mixed
American Century	0	109,809	Withhold
Goldman Sachs	0	91,413	Withhold
Exchange Place Advisors Trust	84,620	0	For
Northern Trust	73,540	0	For
ProShares	0	64,795	Withhold
Voya	56,077	0	For
ALPS ETF Trust	0	53,700	Withhold
AIG/SunAmerica	0	34,775	Withhold
Brighthouse	0	34,572	Withhold
Global X	32,116	0	For

Showing the 25 largest of 58 asset managers. See all 58 in the interactive database.

2. Elect Director: Troy E. Wilson, Ph.D., J.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%

FOR: 59,332,182WITHHELD: 7,740,382

Details: description as filed, official tally, votes by 58 asset managers

Description as filed by funds: Election of two Class I directors for three-year terms: Troy E. Wilson, Ph.D, J.D.

KURA ONCOLOGY INC.’s own tally for this item (“Elect Director: Troy E. Wilson, Ph.D., J.D.”): 59,332,182 for, 7,740,382 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 88% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 58 asset managers below reported 14,657,815 for, 1,810,549 withheld.

FOR

FOR: 14,657,815WITHHOLD: 1,810,549

Largest asset managers voting on “Election of two Class I directors for three-year terms: Troy E. Wilson, Ph.D, J.D.” at KURA ONCOLOGY INC., 2023-2024
Asset manager	For	Withheld	Vote
Vanguard	3,968,562	0	For
BlackRock	3,144,096	0	For
State Street	2,554,088	37,562	For
Fidelity	1,706,693	0	For
Dimensional	0	996,915	Withhold
FRANKLIN STRATEGIC SERIES	967,982	0	For
Charles Schwab	599,027	0	For
JPMorgan	305,460	0	For
Direxion Shares ETF Trust	0	213,276	Withhold
Invesco	203,663	0	For
Equitable	191,066	0	For
TIAA	175,690	0	For
Russell Investments	150,483	0	For
QUANTITATIVE MASTER SERIES LLC	131,528	0	For
Lincoln Financial	82,663	38,615	Mixed
American Century	0	109,809	Withhold
Goldman Sachs	91,413	0	For
Exchange Place Advisors Trust	84,620	0	For
Northern Trust	73,540	0	For
ProShares	0	64,795	Withhold
Voya	0	56,077	Withhold
ALPS ETF Trust	0	53,700	Withhold
AIG/SunAmerica	0	34,775	Withhold
Brighthouse	0	34,572	Withhold
Global X	32,116	0	For

Showing the 25 largest of 58 asset managers. See all 58 in the interactive database.

3. 4. Approval of our Amended 2014 Plan

Official resultCOMPENSATIONReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

82% Approved · of votes cast

FOR 82%AGAINST

FOR: 53,621,818AGAINST: 11,993,394

Details: description as filed, official tally, votes by 60 asset managers

Description as filed by funds: APPROVAL OF AN AMENDMENT TO OUR AMENDED AND RESTATED 2014 EQUITY INCENTIVE PLAN.

KURA ONCOLOGY INC.’s own tally for this item (“4. Approval of our Amended 2014 Plan”): 53,621,818 for, 11,993,394 against — passed, per its Form 8-K filed June 7, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(4) approved our Amended 2014 Plan as disclosed in the proxy statement”
Support: 82% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of KURA ONCOLOGY INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Amend Stock Compensation Plan” (2 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).

The 60 asset managers below reported 11,960,362 for, 4,555,563 against.

FORAGAINST

FOR: 11,960,362AGAINST: 4,555,563

Largest asset managers voting on “APPROVAL OF AN AMENDMENT TO OUR AMENDED AND RESTATED 2014 EQUITY INCENTIVE PLAN.” at KURA ONCOLOGY INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	3,968,562	0	For
BlackRock	3,144,096	0	For
State Street	27,922	2,563,728	Against
Fidelity	1,641,779	64,914	For
Dimensional	0	996,915	Against
FRANKLIN STRATEGIC SERIES	967,982	0	For
Charles Schwab	599,027	0	For
JPMorgan	305,460	0	For
Direxion Shares ETF Trust	0	213,276	Against
Invesco	203,663	0	For
Equitable	191,066	0	For
TIAA	175,690	0	For
Russell Investments	150,483	0	For
QUANTITATIVE MASTER SERIES LLC	131,528	0	For
Lincoln Financial	25,564	95,714	Mixed
American Century	0	109,809	Against
Goldman Sachs	0	91,413	Against
Exchange Place Advisors Trust	84,620	0	For
Northern Trust	73,540	0	For
ProShares	0	64,795	Against
Voya	0	56,077	Against
ALPS ETF Trust	0	53,700	Against
ALGERT GLOBAL LLC	47,561	0	For
AIG/SunAmerica	0	34,775	Against
Brighthouse	0	34,572	Against

Showing the 25 largest of 60 asset managers. See all 60 in the interactive database.

4. 3. Advisory Vote on Executive Compensation

Official result Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 9 wordings of this item as funds reported it.

92% Approved · of votes cast

FOR 92%

FOR: 61,538,693AGAINST: 5,449,767

Details: description as filed, official tally, votes by 183 asset managers

Description as filed by funds: APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS DURING THE YEAR ENDED DECEMBER 31, 2023.

KURA ONCOLOGY INC.’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 61,538,693 for, 5,449,767 against — passed, per its Form 8-K filed June 7, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(3) approved, on an advisory basis, the compensation paid to our named executive officers as disclosed in the proxy statement”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 59 asset managers voting on “APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS DURING THE YEAR ENDED DECE” at KURA ONCOLOGY INC., 2023-2024
Asset manager	For	Against	Withheld	Vote
Vanguard	3,968,562	0	0	For
BlackRock	3,144,096	0	0	For
State Street	2,591,650	0	0	For
Fidelity	1,706,693	0	0	For
Dimensional	0	996,915	0	Against
FRANKLIN STRATEGIC SERIES	0	967,982	0	Against
Charles Schwab	0	599,027	0	Against
JPMorgan	305,460	0	0	For
Direxion Shares ETF Trust	213,276	0	0	For
Invesco	203,663	0	0	For
Equitable	191,066	0	0	For
TIAA	175,690	0	0	For
Russell Investments	0	150,483	0	Against
QUANTITATIVE MASTER SERIES LLC	131,528	0	0	For
Lincoln Financial	113,592	7,686	0	Mixed
American Century	109,809	0	0	For
Goldman Sachs	91,413	0	0	For
Exchange Place Advisors Trust	0	84,620	0	Against
Simplify Exchange Traded Funds	0	0	80,000	Withhold
Northern Trust	73,540	0	0	For
ProShares	64,795	0	0	For
Voya	56,077	0	0	For
ALPS ETF Trust	53,700	0	0	For
AIG/SunAmerica	34,775	0	0	For
Brighthouse	34,572	0	0	For

Fund voting reports, all 59 managers: 13,539,462 for, 2,928,902 against, 80,000 withheld. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 144 asset managers voting on “APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS DURING THE YEAR ENDED DECE” at KURA ONCOLOGY INC., 2023-2024
Asset manager	For	Against	Vote
New York Life	19,000,000	0	For
EcoR1 Capital, LLC	5,806,871	0	For
SUVRETTA CAPITAL MANAGEMENT, LLC	5,570,766	0	For
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	5,411,571	0	For
BVF INC/IL	4,876,293	0	For
State Street	3,985,203	0	For
BlackRock	2,739,482	9,112	For
Avoro Capital Advisors LLC	2,544,742	0	For
Paradigm Biocapital Advisors LP	2,398,541	0	For
Foresite Capital Management IV, LLC	1,849,947	0	For
ARMISTICE CAPITAL, LLC	1,738,699	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,705,203	0	For
FRANKLIN ADVISERS INC	30,929	1,510,138	Against
COMMODORE CAPITAL LP	1,525,000	0	For
TCG Crossover Management, LLC	1,423,642	0	For
Candriam S.C.A.	0	651,398	Against
Charles Schwab	0	599,027	Against
Northern Trust	580,277	733	For
DAFNA Capital Management LLC	412,663	0	For
Sofinnova Investments, Inc.	381,412	0	For
JPMorgan	372,486	0	For
Verition Fund Management LLC	348,007	0	For
Affinity Asset Advisors, LLC	346,954	0	For
MELLON INVESTMENTS Corp	305,390	0	For
Logos Global Management LP	0	300,000	Against

No total is shown for the institutional-manager reports: their sum exceeds the total votes cast at the meeting. Showing the 25 largest; see all in the interactive database.

5. 2. Ratification of the Selection of Independent Registered Public Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%

FOR: 69,596,811AGAINST: 56,740

Details: description as filed, official tally, votes by 58 asset managers

Description as filed by funds: RATIFICATION OF THE SELECTION OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2024.

KURA ONCOLOGY INC.’s own tally for this item (“2. Ratification of the Selection of Independent Registered Public Accounting Firm”): 69,596,811 for, 56,740 against — passed, per its Form 8-K filed June 7, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(2) ratified the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 58 asset managers below reported 16,463,928 for, 4,436 against.

FOR

FOR: 16,463,928AGAINST: 4,436

Largest asset managers voting on “RATIFICATION OF THE SELECTION OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OU” at KURA ONCOLOGY INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	3,968,562	0	For
BlackRock	3,144,096	0	For
State Street	2,587,214	4,436	For
Fidelity	1,706,693	0	For
Dimensional	996,915	0	For
FRANKLIN STRATEGIC SERIES	967,982	0	For
Charles Schwab	599,027	0	For
JPMorgan	305,460	0	For
Direxion Shares ETF Trust	213,276	0	For
Invesco	203,663	0	For
Equitable	191,066	0	For
TIAA	175,690	0	For
Russell Investments	150,483	0	For
QUANTITATIVE MASTER SERIES LLC	131,528	0	For
Lincoln Financial	121,278	0	For
American Century	109,809	0	For
Goldman Sachs	91,413	0	For
Exchange Place Advisors Trust	84,620	0	For
Northern Trust	73,540	0	For
ProShares	64,795	0	For
Voya	56,077	0	For
ALPS ETF Trust	53,700	0	For
AIG/SunAmerica	34,775	0	For
Brighthouse	34,572	0	For
Global X	32,116	0	For

Showing the 25 largest of 58 asset managers. See all 58 in the interactive database.

Largest KURA ONCOLOGY INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 76,181,000 shares outstanding at the time of that meeting.

Fund voting reports: top KURA ONCOLOGY INC. shareholders by shares voted on “APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS DURING THE…”, 2023-2024
#	Asset manager	% of shares outstanding
1	Vanguard	5.21%
2	BlackRock	4.13%
3	State Street	3.40%
4	Fidelity	2.24%
5	Dimensional	1.31%
6	FRANKLIN STRATEGIC SERIES	1.27%
7	Charles Schwab	0.79%
8	JPMorgan	0.40%
9	Direxion Shares ETF Trust	0.28%
10	Invesco	0.27%

Institutional-manager reports: top KURA ONCOLOGY INC. shareholders by shares voted on “APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS DURING THE…”, 2023-2024
#	Asset manager	% of shares outstanding
1	New York Life	24.94%
2	EcoR1 Capital, LLC	7.62%
3	SUVRETTA CAPITAL MANAGEMENT, LLC	7.31%
4	DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	7.10%
5	BVF INC/IL	6.40%
6	State Street	5.23%
7	BlackRock	3.61%
8	Avoro Capital Advisors LLC	3.34%
9	Paradigm Biocapital Advisors LP	3.15%
10	Foresite Capital Management IV, LLC	2.43%

Reported KURA ONCOLOGY INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

KURA ONCOLOGY INC. holdings and ownership disclosed for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
BlackRock	12.49%	13F
EcoR1 Capital, LLC	10.09%	DEF14A
Suvretta Capital Management, LLC	10.07%	DEF14A
BVF Partners L.P.	10.02%	DEF14A
S	9.81%	13G
Deerfield Management Company, L.P.	7.66%	DEF14A
Vanguard Group	7.18%	13F
State Street	5.51%	13F
Goldman Sachs	3.43%	13F
Troy E. Wilson, Ph.D., J.D.	3.01%	DEF14A

Percentages above are of 76,181,000 shares outstanding, as reported by KURA ONCOLOGY INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from KURA ONCOLOGY INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.

At KURA ONCOLOGY INC.'s shareholder meeting held June 5, 2024, in the 2023-2024 proxy season, 183 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 1,100 separate fund positions. On the most widely held item on that ballot — APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS DURING THE… — KURA ONCOLOGY INC.'s filing reports the proposal as approved, with 92% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: KURA ONCOLOGY INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 7, 2024.

KURA ONCOLOGY INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Download data (CSV): ballot items · votes by manager · column guide.